Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
$50.51
-2.2%
$43.65
$15.80
$94.90
$3.60B-1.5938,831 shs179,204 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,152.16
-2.5%
$1,103.63
$623.78
$1,249.45
$1.09T0.513.18 million shs1.09 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$48.91
-0.8%
$45.71
$35.12
$71.79
$218.40B0.7718.88 million shs2.67 million shs
Sanofi stock logo
SNY
Sanofi
$43.23
-1.8%
$43.30
$40.89
$52.68
$104.74B0.343.62 million shs910,950 shs
10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-3.22%-5.68%+20.29%-2.91%+171.65%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.28%-1.26%+4.28%+28.49%+49.46%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-0.42%0.00%+12.25%+25.30%-28.51%
Sanofi stock logo
SNY
Sanofi
+1.15%+3.26%-0.56%-7.64%-9.48%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
$50.51
-2.2%
$43.65
$15.80
$94.90
$3.60B-1.5938,831 shs179,204 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,152.16
-2.5%
$1,103.63
$623.78
$1,249.45
$1.09T0.513.18 million shs1.09 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$48.91
-0.8%
$45.71
$35.12
$71.79
$218.40B0.7718.88 million shs2.67 million shs
Sanofi stock logo
SNY
Sanofi
$43.23
-1.8%
$43.30
$40.89
$52.68
$104.74B0.343.62 million shs910,950 shs
10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-3.22%-5.68%+20.29%-2.91%+171.65%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.28%-1.26%+4.28%+28.49%+49.46%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-0.42%0.00%+12.25%+25.30%-28.51%
Sanofi stock logo
SNY
Sanofi
+1.15%+3.26%-0.56%-7.64%-9.48%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
2.89
Moderate Buy$110.55118.88% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,271.9310.39% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.17
Hold$65.5634.05% Upside
Sanofi stock logo
SNY
Sanofi
2.47
Hold$49.5014.51% Upside

Current Analyst Ratings Breakdown

Latest LLY, GPCR, SNY, and NVO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/14/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform
7/14/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOutperform$1,300.00 ➝ $1,385.00
7/13/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,250.00 ➝ $1,425.00
7/13/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,235.00 ➝ $1,273.00
7/10/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,251.00 ➝ $1,334.00
7/9/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Set Price Target$1,370.00
7/8/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,281.00 ➝ $1,370.00
7/8/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,344.00 ➝ $1,347.00
7/8/2026
Sanofi stock logo
SNY
Sanofi
Set Price Target$49.00
7/8/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOutperform$1,250.00 ➝ $1,500.00
7/7/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,300.00 ➝ $1,400.00
(Data available from 7/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/A$24.99 per shareN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B16.65$24.37 per share47.28$28.07 per share41.05
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.80B4.67$4.63 per share10.56$6.58 per share7.43
Sanofi stock logo
SNY
Sanofi
$49.35B2.12$7.02 per share6.16$33.26 per share1.30
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$141.20M-$0.87N/AN/AN/AN/A-24.91%-23.67%8/6/2026 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1540.9525.211.4734.98%105.77%23.76%8/5/2026 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$4.2611.4814.964.5137.23%63.31%22.19%8/5/2026 (Estimated)
Sanofi stock logo
SNY
Sanofi
$8.84B$3.5812.078.381.1116.95%13.39%7.58%7/30/2026 (Estimated)

Latest LLY, GPCR, SNY, and NVO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$0.39N/AN/AN/AN/AN/A
8/5/2026Q2 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$8.82N/AN/AN/A$20.53 billionN/A
8/5/2026Q2 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.82N/AN/AN/A$10.99 billionN/A
7/30/2026Q2 2026
Sanofi stock logo
SNY
Sanofi
$1.09N/AN/AN/A$12.76 billionN/A
5/7/2026Q1 2026
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$0.39-$0.35+$0.04-$0.35$11.11 millionN/A
5/6/2026Q1 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.87$1.04+$0.17$1.69$10.86 billion$10.85 billion
4/30/2026Q1 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.60%+15.18%24.58%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.753.58%+21.74%41.08%N/A
Sanofi stock logo
SNY
Sanofi
$1.764.07%+6.46%49.16%N/A

Latest LLY, GPCR, SNY, and NVO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/22/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.63%8/14/20268/14/20269/10/2026
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.69%5/15/20265/15/20266/10/2026
4/14/2026
Sanofi stock logo
SNY
Sanofi
annual$2.42255.59%5/4/20265/4/20266/3/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/A
26.16
26.16
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.59
0.79
0.56
Sanofi stock logo
SNY
Sanofi
0.17
1.01
0.22

Institutional Ownership

CompanyInstitutional Ownership
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
91.78%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Sanofi stock logo
SNY
Sanofi
14.03%

Insider Ownership

CompanyInsider Ownership
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
5.50%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
Sanofi stock logo
SNY
Sanofi
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
13671.07 million67.17 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable
Sanofi stock logo
SNY
Sanofi
74,8462.42 billion2.40 billionOptionable

Recent News About These Companies

Sanofi ADR
Sanofi SA ADR SNY N
Sanofi Faces EU Probe With Fines Possibly Reaching 10%

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Structure Therapeutics stock logo

Structure Therapeutics NASDAQ:GPCR

$50.50 -1.14 (-2.20%)
As of 12:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,152.16 -29.71 (-2.51%)
As of 12:24 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$48.91 -0.37 (-0.75%)
As of 12:24 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Sanofi stock logo

Sanofi NASDAQ:SNY

$43.23 -0.77 (-1.75%)
As of 12:24 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.